United States - English - NLM (National Library of Medicine)

auromedics pharma llc - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin 2 g - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (see clinical pharmacology - susceptibility test methods .) oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. oxacillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or str

United States - English - NLM (National Library of Medicine)

auromedics pharma llc - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin 10 g in 100 ml - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (see clinical pharmacology - susceptibility test methods .) oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. oxacillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or stro

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - piperacillin sodium; tazobactam sodium -

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc. - nafcillin sodium (unii: 49g3001bck) (nafcillin - unii:4cnz27m7rv) - nafcillin 1 g - nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology - susceptibility tests ). nafcillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. nafcillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with nafcillin for injection, usp. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection and other antibacterial drugs, nafcillin for injection should be used only to treat or prevent infections that are proven or strongly sus

Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - a, s - solution for injection/infusion - ampicillin sodium 1 g sulbactam sodium 0.5 g - antibacterials for systemic use

Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - a, s - powder for solution for injection/infusion - ampicillin sodium 2 g sulbactam sodium 1 g - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

truemed group llc - dicloxacillin (unii: cof19h7wbk) (dicloxacillin - unii:cof19h7wbk) -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - linezolid 20 mg/ml - granules for oral suspension - 20 mg/ml - active: linezolid 20 mg/ml excipient: ammonium glycyrrhizinate aspartame citric acid monohydrate colloidal silicon dioxide dispersible cellulose sweet-am powder #918.005 nor-cap natural & artificial orange cream mannitol orange flavour (cream) 884.010 orange flavour 884.114 peppermint flavour sd f93125 sodium benzoate sodium chloride sodium citrate dihydrate sucrose sweet flavour (am) 918.005 vanilla flavour 712729 (mc008927) xanthan gum - zyvox is indicated for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: · pneumonia - community acquired and nosocomial pneumonia · skin and soft tissue infections · enterococcal infections. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - linezolid, quantity: 20.4 mg/ml - oral liquid, suspension - excipient ingredients: mannitol; citric acid; sodium benzoate; aspartame; sodium citrate dihydrate; colloidal anhydrous silica; sucrose; microcrystalline cellulose; sodium chloride; xanthan gum; carmellose sodium; flavour; sorbitol; ammonium glycyrrhizinate; fructose - zyvox is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. zyvox (linezolid) is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: carnauba wax; maize starch; hyprolose; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 400; propylene glycol; butan-1-ol; purified water; iron oxide red; strong ammonia solution; ethyl acetate; ethanol; shellac - zyvox is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. zyvox (linezolid) is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.